N
VTYX

Nuveen’s Ventyx Biosciences VTYX Stock Holding History

Nuveen’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-168,420
Closed -$194K – 3421
2025
Q1 		$194K Hold
168,420
– – ﹤0.01% 3138
2024
Q4 		$369K Hold
168,420
– – ﹤0.01% 3083
2024
Q3 		$367K Buy
168,420
+34,376
+26% +$79K ﹤0.01% 3104
2024
Q2 		$310K Hold
134,044
– – ﹤0.01% 3144
2024
Q1 		$737K Sell
134,044
-54,703
-29% -$250K ﹤0.01% 2827
2023
Q4 		$466K Sell
188,747
-198,525
-51% -$1.89M ﹤0.01% 3030
2023
Q3 		$13.4M Buy
387,272
+21,158
+6% +$731K ﹤0.01% 1298
2023
Q2 		$12M Buy
366,114
+153,936
+73% +$5.31M ﹤0.01% 1390
2023
Q1 		$7.11M Buy
212,178
+19,245
+10% +$748K ﹤0.01% 1687
2022
Q4 		$6.33M Buy
192,933
+123,882
+179% +$3.67M ﹤0.01% 1783
2022
Q3 		$2.41M Sell
69,051
-432
-0.6% -$9.56K ﹤0.01% 2301
2022
Q2 		$850K Buy
69,483
+53,654
+339% +$802K ﹤0.01% 2865
2022
Q1 		$215K Hold
15,829
– – ﹤0.01% 3178
2021
Q4 		$314K Buy
+15,829
New +$300K ﹤0.01% 3171

Other funds holding VTYX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Nuveen's VTYX Position: Q2 2025 in Review

Nuveen sold out of Ventyx Biosciences (VTYX) in Q2 2025, closing a stake of 168,420 shares — an estimated $194K sold.

Nuveen first reported a position in VTYX in Q4 2021 and held it in 14 quarters. The position peaked at $13.4M in Q3 2023. 114 funds tracked by Wall St. Rank hold VTYX as of Q2 2025.

  • Nuveen reported no remaining Ventyx Biosciences position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 168,420 Ventyx Biosciences shares in Q2 2025, an estimated $194K.
  • Nuveen first reported a position in Ventyx Biosciences in Q4 2021 and held it in 14 quarters.
  • Nuveen's Ventyx Biosciences position peaked at $13.4M in Q3 2023.
  • 114 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.